Improving quality of life after breast cancer: dealing with symptoms.

Maturitas

Department of Medical Oncology, Portuguese Institute of Oncology Francisco Gentil, EPE-Coimbra, Coimbra, Portugal.

Published: December 2011

Background: Advances in breast cancer therapies have given rise to a growing number of patient survivors. Nevertheless, these women deal with long-term sequelae that impair their quality of life and that are lacking satisfactory assessment and expeditious management. Importantly, a new era is raising in the oncology field, namely, survivorship.

Methods: A search for English-language articles on Medline was undertaken covering the last 15 years, using the terms "cancer survivorship", "quality of life", "fatigue", "insomnia", "sleep disturbances", "depression", "cognitive dysfunction", "chemofog", "peripheral neuropathy", "fertility", "sexual behaviour", "menopause", "lymphedema", "physical activity" and "breast neoplasms". Selection was limited to systematic reviews and meta-analysis, but their reference list was examined to include papers of potential interest.

Results: We found the most common symptoms affecting breast cancer survivors were fatigue, insomnia, depression, cognitive dysfunction, reproductive and menopausal symptoms and lymphoedema.

Conclusion: Some of these symptoms have even been the objective of randomised controlled trials, but consistent data are missing. The available interventions include pharmacological, behavioural therapies and complementary and alternative medicine approaches and will mostly depend on the type of symptom.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.maturitas.2011.09.008DOI Listing

Publication Analysis

Top Keywords

breast cancer
12
quality life
8
improving quality
4
life breast
4
cancer dealing
4
symptoms
4
dealing symptoms
4
symptoms background
4
background advances
4
advances breast
4

Similar Publications

Study Objectives: Cancer-related fatigue is one of the most common symptoms in cancer survivors. Cognitive behavioural therapy for insomnia (CBT-I) can improve fatigue, but mechanisms are unclear. This secondary analysis of a randomized controlled trial evaluated whether CBT-I led to a significant improvement in fatigue, accounting for change in comorbid symptoms of insomnia, perceived cognitive impairment (PCI), anxiety, and depression.

View Article and Find Full Text PDF

The efficacy of photodynamic treatment (PDT) against deep-seated tumor is hindered by low penetration depth of light as well as hypoxic conditions which prevails in tumor. To overcome this limitation, Near-infrared (NIR) absorbing photosensitizers have been investigated actively. In the present study we evaluated the PDT efficacy of an NIR absorbing chlorophyll derivative 'Cycloimide Purpurin-18 (CIPp-18)' in Human Breast carcinoma (MCF-7) and cervical adenocarcinoma (Hela) cells under normoxic and hypoxic conditions.

View Article and Find Full Text PDF

Purpose Of Review: Male breast cancer (MBC) is a rare entity which often arises in elderly people. Aim of this review is to evaluate the principal issues related to MBC in elderly, because the therapeutic management of disease is not only related to the biological behavior of the tumor, but also to the comorbidities and frailty of older population. A scoping literature review was performed on Pubmed and Cochrane Database using the following keywords: therapeutic management/ male/ breast cancer/ elderly patients.

View Article and Find Full Text PDF

Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.

Cancer Commun (Lond)

January 2025

Department of Medical Oncology, Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, P. R. China.

Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti-HER2 bispecific antibody, plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.

Methods: This open-label, single-arm, phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30, 2019 to May 27, 2021.

View Article and Find Full Text PDF

Background: Population-level mammography screening for early detection of breast cancer is a secondary prevention measure well-embedded in developed countries, and the implications for women's health are widely researched. From a public health perspective, efforts have focused on why mammography screening rates remain below the 70% screening rate required for effective population-level screening. From a sociological perspective, debates centre on whether 'informed choice' regarding screening exists for all women and the overemphasis on screening benefits, at the cost of not highlighting the potential harms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!